- Divi’s Labs reported a net income of 5.89 billion rupees for the third quarter, which is a 65% growth year-over-year. This figure surpasses the estimated net income of 5 billion rupees.
- The company’s revenue for the quarter was 23.2 billion rupees, showing a 25% increase from the previous year, and exceeding the estimated 22.55 billion rupees.
- Total costs for Divi’s Labs were 16.8 billion rupees, marking a 15% rise compared to the previous year.
- Raw material costs reached 10.2 billion rupees, reflecting a 28% increase year-over-year.
- Employee benefits expenses were recorded at 2.97 billion rupees, an 11% increase from the prior year but slightly below the estimated 3.04 billion rupees.
- Other income was 820 million rupees, showing a decrease of 14% from the previous year.
- The company began operations at part of its Kakinada Project on January 1.
- The remaining parts of the Kakinada Project are under implementation, with expectations to be operational in approximately six months.
- Analyst recommendations include 10 buys, 5 holds, and 13 sells.
“`
Divi’s Laboratories on Smartkarma
Analyst coverage of Divi’s Laboratories on Smartkarma by Janaghan Jeyakumar, CFA shows a bearish sentiment in the latest research report titled “Quiddity NIFTY Sep 24 Rebal: US$647mn One-Way Capping for NIFTY Next 50; All Changes Were Predicted.” The report highlights upcoming changes in the NIFTY indices scheduled for September 27, 2024. These changes include two for NIFTY 50 and five for NIFTY 100, all of which were accurately predicted by the analyst. The expected impact on the NIFTY Next 50 index could involve significant one-way capping flows amounting to US$647mn.
For more insights and detailed analysis on this and other companies, investors can refer to Janaghan Jeyakumar’s research report on Smartkarma. The report provides valuable information on the upcoming NIFTY index rebalance events and how they might influence the market. Investors interested in understanding the implications of these changes on Divi’s Laboratories and other related companies can benefit from the in-depth analysis conducted by the analyst.
A look at Divi’s Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Divi’s Laboratories Ltd. has received a promising assessment based on the Smartkarma Smart Scores. With notable ratings for Resilience and Momentum at 5 and 4 respectively, the company showcases a strong ability to weather market uncertainties and maintain positive stock performance. The solid scores in Growth and Dividend further indicate a favorable long-term outlook for investors, suggesting potential for steady expansion and returns.
As a pharmaceutical manufacturer specializing in generic drugs and research services, Divi’s Laboratories is positioned to benefit from its diversified operations. The encouraging Smart Scores emphasize the company’s overall health and growth potential, making it an attractive prospect for investors seeking stability and growth in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
